advertisement
ATC Level5: A16AB04 - Agalsidase Beta
ATC Level1:
- A - Alimentary tract and metabolism
ATC Level2:
- A16 - Other alimentary tract and metabolism products
ATC Level3:
- A16A - Other alimentary tract and metabolism products
ATC Level4:
ATC Level5:
- A16AB04 - Agalsidase Beta
Drugs in ATC category "A16AB04":
- Agalsidase Beta
- 1 INDICATIONS AND USAGE Fabrazyme ® (agalsidase beta) is indicated for use in patients with Fabry disease. Fabrazyme reduces globotriaosylceramide (GL‑3) deposition in capillary endothelium of the kidney and certain other cell types. Fabrazyme is indicated for use in patients with Fabry disease. Fabrazyme...
- Fabrazyme
- Agalsidase beta belongs to the group of medications known as enzyme replacement therapy. It is used as enzyme replacement therapy for people with Fabry disease, which is a genetic disorder where the levels of alpha-galactosidase (an enzyme that breaks down fats) is low or absent. With Fabry disease, globotriaosylceramide (or GL-3; a fat substance) is not removed from cells in the body and starts to accumulate in the walls of blood vessels and organs. By reducing GL-3 levels in the body,...
advertisement
The information was verified by Dr. Rachana Salvi, MD Pharmacology
© 2002 - 2024 "sdrugs.com". All Rights Reserved